Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Real-World Oral Antiviral Efficacy and COVID-19 Rebound

Hear expert insights on oral antiviral efficacy in real-world populations and COVID-19 rebound phenomenon.
Arthur Kim, MD
Released: August 5, 2022

Information on this Educational Activity

Faculty

Arthur Kim, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Viral Hepatitis Clinic
Division of Infectious Diseases
Massachusetts General Hospital
Boston, Massachusetts

Arthur Kim, MD: drug and safety monitoring board: Kintor.

Program Medium

This program has been made available online.

Related Content

Dr Helen Chu shares how the COVID-19 pandemic has influenced RSV diagnostic and prevention efforts, from Clinical Care Options (CCO)

Helen Y. Chu, MD, MPH Released: January 31, 2023

Learn from Dr Zhuxin Mao about emerging data on quantifying quality of life of older adults with RSV, from Clinical Care Options (CCO)

person default Zhuxin Moa, PhD Released: January 30, 2023

This downloadable PDF reviews a treatment pathway for nonhospitalized patients with COVID-19, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Renslow Sherer, MD Released: January 17, 2023

Dr Stephaun Elite Wallace on COVID-19 inequities in BIPOC communities and strategies to minimize these disparities, from Clinical Care Options (CCO), Practicing Clinicians Exchange (PCE), and ProCE

Stephaun Elite Wallace, PhD, MS Released: January 17, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings